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Abstract. A total of 255 patients including 179 (70.2%) of non-HIV and 76 (29.8%) HIV-infected patients 
were recruited in this descriptive study. The subjects was significantly found to be male Chinese (157; 
61.6% vs 74; 47.1%) followed by female Malays (98; 38.4% vs 35; 35.7%) (p<0.05).  The majority 
of subjects (124; 48.6%) were in the age group of 21-39 years, however, no statistical difference was 
found between the various age groups (p>0.05). Overall seroprevalence of latent Toxoplasma infection 
was 82/183 (44.8%) being; 3 (3.7%) positive for IgM, 74 (90.2%) for IgG, and 5 (6.1%) for IgG and 
IgM antibodies.  The prevalence was more relatively found in the Chinese (28; 15.3%) and Malays (27; 
14.8%) than others (p<0.05).  While, 23/76 (30.3%) of HIV-positive patients were shown Toxoplasma 
seropositivity.  The majority of these subjects (138/181; 76.2%) were significantly asymptomatic (p = 
0.000), while the others were clinically evident cases of toxoplasmosis.  Of this, 37 patients were included 
in differential diagnosis relating to ocular diseases and only 4 patients were confirmed as having ocular 
toxoplasmosis.  Toxoplasmic encephalitis (TE) was based on presumptive diagnosis, particularly found in 
5 patients with AIDS. Seventeen patients were clinically diagnosed as having malaria being; 8 for P. vivax, 
4 for P. falciparum, 3 for P. malariae, and 2 for mixed infections.  All cases resolved satisfactorily after 
treatment with antimalarial drugs. Other important emerging parasitic diseases were also detected in 
these patients including amebiasis (2), blastocystosis (1), cryptosporidiosis (1), filariasis (1), and giardiasis 
(2) during the time of this study.  
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IntroDuCtIon
 Parasitic infections have historically been 
some of the most common causes of human 
disease; which pose economic, health, and social 
problems to the people living in developing 
countries, including Malaysia. the impact 
of parasitic infections on human lives has 
been a topic of great interest in the field of 
tropical medicine.  We therefore conducted this 
study to determine the prevalence of parasitic 
infections and the incidence of clinical cases 
of these diseases from patients admitted to the 
university of Malaya Medical Center (uMMC), 
kuala Lumpur.  this data will further enhance 
the existing baseline information and the 
implementation of the standard strategies in terms 
of prevention and proper management.
MAtErIALS AnD MEtHoDS
Patients
 this retrospective and descriptive study was 
carried out at the Department of Parasitology, 
university of Malaya Medical Center (uMMC), 
kuala Lumpur, Malaysia.  this institution is the 
oldest university tertiary referral hospital, with 863 
beds.  It serves as a focus for public services and as 
a teaching center.  Data  from a total of 255 patients, 
including 179 (70.2%) of non-HIV and 76 (29.8%) 
of HIV-positive patients, were collected and 
recorded, including laboratory results from blood, 
serum, and stool samples, in the standardized data 
collection sheet during May 2004 to February 
2006.  All positive cases were further investigated, 
based on the patients’ demographic profiles, 
clinical presentations, relevant laboratory data, and 
their treatment outcome, from the medical record 
office, university of Malaya Medical Center.  the 
patients’ information was included in the same 
questionnaire.
Diagnosis of diseases
 Various investigations were carefully reviewed 
according to our study’s objectives.  the standard 
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criteria for diagnosing these parasitic infections 
are as follows:  
 1. Diagnosis of giardiasis was made by stool 
examination (concentration technique) for the 
present of Giardia trophozoites or cysts. 
 2. Diagnosis of cryptosporidiosis was made 
by the stool examination for the presence of 
Cryptosporidium oocysts and confirmed by 
modified Ziehl-neelsen staining techniques. 
 3. Diagnosis of malaria was made by 
microscopic identification of peripheral blood 
smear to detect the presence of Plasmodium spp. 
Also, noW®  MALArIA, uSA was serologically 
used for the antigen detection of Plasmodium 
spp.
 4. Diagnosis of seropositivity for Toxo-
plasma infection was via detection of anti-
Toxoplasma IgG, IgM, or both by either 
one of the standard ELISA commercial kits 
(trinity Biotech, Bray, Ireland; Veda-lab, 
Alencon Cedex, France) in accordance with the 
manufacturer’s instruction. 
 5.  Diagnosis of seropositive for amobiasis 
was detected by serologic tests such as IHA 
or Cellognost® Amoebasis, uSA. For filarial 
infections, peripheral blood smear was used to 
detect the presence of filarial worms. Few of 
serological diagnostic kits were available for the 
antigen detection of Brugia spp and Wuchereria 
bancrofti (noW® ICt FILArIASIS, uSA), 
also for the antibodies detection of Brugia spp 
(BRUGIArapidtM, Malaysia) and Wuchereria 
bancrofti (WB Malaysia). Positive results of 
these parasitic infections were identified by 
experienced technicians and confirmed by clinical 
consultants.
 6. Clinical toxoplasmosis was detected in the 
different two groups of patient, and the diagnoses 
were determined for a) ocular toxoplasmosis, 
by clinical presenting signs and symptoms, 
opthalmoscopic examination, serodiagnosis 
of Toxoplasma infection, and responses to 
anti-Toxoplasma therapy, and b) congenital 
encephalitis was diagnosed by anti-HIV-positive 
status, CD4 <200 cells/mm3 (excluded from other 
of immunocompromised), neurological signs 
and symptoms, seroevidence of anti-Toxoplasma 
antibodies, and response to anti-Toxoplasma 
therapy.
Statistical analysis
 All the findings obtained were entered, edited, 
and analyzed using statistical software, SPSS 
version 10 (SPSS Inc, Chicago, uSA).  the data 
with quantitative variables were expressed as 
median and range; whereas, qualitative variables 
were expressed as frequency and percentage. 
Statistical analyses were estimated using either 
the chi-square test or Student’s t test, where 
appropriate.  A p-value of <0.05 was regarded 
as statistically significant. 
rESuLtS
 the demographic profiles of the study subjects 
during May 2004 to February 2006 (21 months) 
are presented in table 1.  A total of 255 patients, 
including 179 (70.2%) of HIV-negative and 76 
(29.8%) HIV-positive patients were recruited into 
this retrospective and descriptive study.  the age 
range was from 1 to 81, with a mean of 38.4 ± 
(SD) 15.31 years.  the male:female sex ratio was 
1.6:1.  the study subjects were significantly found 
to be male Chinese (157; 61.6% vs 74; 47.1%), 
followed by female Malays (98; 38.4% vs 35; 
35.7%) (p < 0.05).  the majority of patients (124; 
48.6%) were in the 21-39 year-old age group; 
however, no statistical difference was found 
between the various age groups.  Interestingly, 
HIV transmission was found more significantly 
in males compared with females (56; 35.7% vs 
20; 20.4%) (p <0.05).
 Toxoplasma seropositive and negative status 
was detected in 181/255 (71.0%) subjects.  the 
overall seroprevalence of Toxoplasma infection 
was 82/181 (45.3%); including 3 (3.7%) positive 
for IgM, 74 (90.2%) for IgG, and 5 (6.1%) for both 
IgG and IgM antibodies (Fig 1).  the age range was 
from 1 to 81 years, with a mean of 40 ± (SD) 14.73 
years.  the sex ratio (M:F) was 1.6:1.  the higher 
prevalent rates were found in males (52; 28.4%) 
and equally distributed in the subjects between 
the age group of 20 to 39 and 40 to 59 years (34; 
18.8%).  However, no statistical difference was 
found between these associations. Interestingly, 
the prevalence was significantly related to local 
racial origins, particularly in Chinese (28; 15.5%) 
and Malays (27; 14.9%), when compared to 
others (p =0.000).  twenty-three (30.3%) of 76 
Vol 38  (suppl 1)  2007 183
table 1
Demographic profiles of 255 study subjects attended at the university of Malaya Medical Centre 
(uMMC) during May 2004 to February 2006.
 Variable no. subjects (255) p-value
  Male n = 157 (%) Female n = 98 ( %) 
Age range = 1-81 years   
Mean = 38.4 (±SD) 15.3 years   
M:F = 1.6:1   
Age group     0.182
	 ≤ 20 11 (7.0) 12 (12.2) 
 21-39 75 (47.8) 48 (49.0) 
 40-59 50 (32.0) 32 (32.7) 
	 ≥ 60 21 (13.4) 6 (6.1) 
race     0.023
 Malay 35 (22.3) 35 (35.7) 
 Chinese 74 (47.1) 29 (29.6) 
 Indian 24 (15.3) 20 (20.4) 
 other 24 (15.3) 14 (14.3) 
Country of origin     0.627
 Malaysia 131 (83.4) 84 (85.7) 
 outsider 26 (16.6) 14 (14.3) 
HIV status     0.010
 Positive 56 (35.7) 20 (20.4) 
 negative or unknown 101 (64.3) 78 (79.6) 
Toxoplasma status     0.879
 Positive 52 (33.1) 30 (30.6) 
 negative 61 (38.9) 38 (38.8) 
 unknown 44 (28.0) 30 (30.6) 
Case of toxoplasmosis     0.000
 Asymptomatic 153 (97.5) 92 (63.9) 
 ocular toxoplasmosis 2 (1.3) 2 (2.0) 
 toxoplasmic encephalitis 2 (1.3) 4 (4.1)
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HIV-positive patients showed seropositivity for 
latent Toxoplasma infection. the majority of 
these subjects (138/181; 76.2%) were significantly 
asymptomatic (p = 0.000), while the others were 
clinically evident cases of toxoplasmosis.  From 
37 patients who were included in differential 
diagnosis related to ocular diseases, 33 of them 
were suspected as having ocular toxoplasmosis 
and the other 4 patients were confirmed cases.  the 
life-threatening condition of toxoplasmosis was 
more commonly found in immunocompromised 
patients, particularly that involving the brain. 
From this study, the designation of toxoplasmic 
encephalitis (tE) was based on presumptive 
diagnosis, including 1 case in a patient with 
lymphoma, and 5 cases in AIDS patients. 
 Concerning malaria, 18 cases were found to 
be positive for peripheral blood smear (17) or 
serological (1) detection for malarial infections, 
including 8 with P. vivax, 4 with P. falciparum, 3 
with P. malariae, and 2 with mixed infections.  of 
these cases, 17 patients were clinically diagnosed 
as having malaria.  twelve cases were found 
among locals, including Chinese (6), Malays (5), 
and an Indian (1).  the other five cases were from 
foreign workers where 4 cases and 1 case came 
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 255 Study subjects
 Protozoa Helminthic parasite
 Intestinal Blood-tissue
 Asymptomatic Malaria Toxoplasmosis 
 Protozoan No. Laboratory No. Laboratory No. Laboratory No.
 Blastocystis hominis 1 Blood smear 17 Serum 183 Serology
 Entamoeba histolytica 1 Serology 1 Seroprevalence  Filaria worm 2
 Trichomonas vaginalis 2   82/181  (44.8%)  toxocara 2
   Clinical case No Asymptomatic  Stool
  Symptomatic P. vivax 8 172/183  (94.0%)  Hookworm 1
 Protozoan Case P. falciparum 4 Clinical case  Asymptomatic
 Amebiasis 1 P. malariae 3 ocular toxoplasmosis 4  4 cases
 Blastocystosis 1 Mixed infections 2 toxoplasmosis (brain) 6 Clinical case
 Cryptosporidiosis 1     Filariasis 1
 Giadiasis 2 
Fig 1- The prevalence and clinically evident cases of parasitic diseases from 255 study subjects during May 2004 to February 
2006.
from India and tanzania, respectively.  Malaria 
occurred more commonly in males (14) and in the 
younger age group (10) between 20 to 39 years. 
All cases resolved satisfactorily after treatment 
with antimalarial drugs.  
 regarding helminthic infections, three cases 
had a seropositive titer for filarial infection, and 
one case was confirmed clinically as having 
filariasis.  three cases were asymptomatic with 
hookworm (1) and Toxocara (2) infections. 
Concerning intestinal protozoan parasites, the 
majority of positive laboratory investigations 
were asymptomatic, including 3 for Blastocystis, 
2 for Trichomonas, and 1 for Entamoeba 
infections.  Among the symptomatic cases, 
there was 1 each for amebiasis, blastocystosis, 
and cryptosporidiosis: in addition, 2 cases were 
diagnosed for giardiasis.  overall, there was no 
report of outbreaks, drug resistance, or death 
relating to any of these parasitic infections during 
the time of this study.  
DISCuSSIon
 Parasitic diseases have been found in both 
immunocompetent and compromised hosts in 
any given geographical distribution.  the clinical 
impacts have been recognized as some of the most 
common infectious, opportunistic, endemic, and 
killer diseases in the regional or global arenas. 
 overall, the incidence of parasitic diseases 
was comparatively lower than a previous study 
conducted in the same setting (nissapatorn et 
al, 2005).  Malaria was the most commonly 
occurring parasitic disease, and P. vivax and P. 
falciparum were the more frequent causes found 
in this study.  Malaria continues to present a 
significant challenge in tropical countries where 
over 2 millions people die each year due to this 
disease.  no drug resistance was identified among 
the affected patients; however, chloroquine 
resistant falciparum malaria has been reported as 
early as in 1963, 1995, and 1998 (Jamaiah et al, 
2005).  the continuing expansion of resistance 
of P. falciparum to antimalarial drugs in common 
use results in the increasing need for different 
drug combinations (Socheat et al, 2003).  this 
is causing great concern, as this species is highly 
prevalent in tropical Africa, the Amazon, and 
Southeast Asia (Le Bras et al, 2006).  Promising 
results from recent vaccine trials carried out in 
malaria-naïve and -endemic populations have 
provided important insights into what will be 
required of a successful vaccine (Ballou, 2005). 
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We hope that with this upcoming solution 
could certainly ease the overwhelming burden 
relating to malaria in term of control program 
management in developing countries.
 toxoplasmosis has been listed as a priority 
among parasitic infections reported in Malaysia. 
Although this silent parasitic infection has long 
been afflicting this country, the seroprevalence 
of latent Toxoplasma infection remains high. 
toxoplasmosis represents a clinical problem that 
focuses the attentions of several specialties due to 
the multiorgan pathology it induces and difficulties 
in evaluating the activity of the morbid process 
(kociecka, 2001).  Due to its medical importance, 
this finding indicated that toxoplasmosis needs 
a high index of suspicion in suspected cases of 
ocular disease, particularly in anterior or posterior 
uveitis. there was no case found in this study 
of reactivated toxoplasmosis diagnosed after 
post surgery.  Interestingly, one study found 
that reactivation of ocular toxoplasmosis might 
develop after LASIk surgery (Barbara et al, 
2005).  therefore, this infectious disease should 
be included in differential diagnosis in both 
medical and surgical involvements with unknown 
etiological origin and clinical presentations 
consistent with toxoplasmosis.
 toxoplasmic encephalitis (tE) is based on 
presumptive diagnosis, and more commonly 
found in AIDS patents compared with other 
groups of immunocompromised patients, 
as indicated in our study as well as others. 
neuropathological conditions associated with 
AIDS are still present in approximately 70-90% 
of patients and can be the result of HIV itself 
or of opportunistic infections (Del Valle and 
Pina-oviedo, 2006).  the majority of patients 
had secondary reactivation of latent Toxoplasma 
infection that predominantly involved the brain 
rather than other organs, as also shown in this 
study.  nevertheless, one study demonstrated 
that ocular or orbital disease might be the first 
manifestation of life-threatening systemic 
toxoplasmosis in HIV-positive patients (Lee et 
al, 2006).  However, universal access to HAArt 
has definitely changed both the mortality and 
morbidity of AIDS (Silva and Araujo, 2005) 
and has remarkably reduced the incidence of 
AIDS defining illnesses including tE (Podlasin 
et al, 2006).  Due to the benefits of HAArt, we 
support the proposal whereby HIV-infected adult 
patients who receive effective HAArt therapy, 
primary and secondary prophylaxis against tE 
can be safely discontinued after the CD4+ t-cell 
count has increased to more than 200 cells/mm3 
for more than 3 months (Miro et al, 2006). 
nevertheless, it would depend on each case, 
where there is a need to evaluate the patients’ 
accessibility, availability and affordability of 
HAArt.  then the use of HAArt would serve 
to treat AIDS-related tE fully without the need 
for chemoprophylaxis.  the combination of 
fansidar and clindamycin is commonly use in 
treating tE in our hospitals. So far, there has 
not been any other superior regimen identified 
for the treatment of tE. the choice of therapy 
will often be determined by the availability of 
a therapy such as tMP-SMX, which appears 
to be an effective alternative therapy for tE in 
resource poor settings where pyrimethamine 
and sulfadiazine are not available (Dedicoat and 
Livesley, 2006).  tE is still being seen as one 
of the most common opportunistic infections in 
patients with AIDS, particularly in this region. 
 Gastrointestinal protozoan parasites pose 
a basic public health concern because of high 
prevalence rates, particularly in the developing 
countries. the problem might be more serious 
because of asymptomatic intestinal parasitic 
infections (nuchprayoon et al, 2002), as also 
might be the case in this study.  our data showed 
5 cases of symptomatic amebiasis, giardiasis, 
and cryptosporidiosis in these patients. of these 
cases, only cryptosporidiosis was diagnosed in 
an AIDS patient who presented with chronic 
diarrhea.  Persistent diarrhea and weight loss are 
the predominant features of cryptosporidiosis 
(Moolasart et al, 1995), and it causes severe 
and chronic life-threatening gastroenteritis in 
immunocompromized patients (Zardi et al, 
2005).  therefore, a high index of suspicion is 
appropriate for this opportunistic pathogen in 
HIV-positive patients who have these specific 
presentations.  
 Cryptosporidiosis has been one of the most 
important parasites that is considered by the 
Centers for Disease Control and Prevention 
(CDC), Atlanta, as an AIDS-defining illness.  In 
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Malaysia, reports of cryptosporidiosis in patients 
with AIDS has been very limited (kamel et al, 
1994; nissapatorn et al, 2003; Lim et al, 2005), 
and not much attention is given, particularly in 
clinical practice.  the possible explanations are 
that the routine but specific diagnostic methods 
have not been established for the laboratory; and, 
despite the efficacy of passive immunotherapy or 
some chemotherapeutic agents (eg, paromomycin 
and nitaxozanide), no significant benefits have 
been demonstrated (Zardi et al, 2005).  With the 
introduction of antiretroviral drugs, one study 
indicated that the increasing immunity due to 
these drugs might be an important factor in the 
prevention of opportunistic protozoan infections 
among HIV-infected patents (Wiwanitkit and 
Srisupanant, 2006).  An increased inhibitory 
effect was demonstrated when aminoglycoside 
paromomycin was combined with the protease 
inhibitors (Hommer et al, 2003), and it could be 
considered as alternative for the development of 
new drugs that might prove effective against this 
enigmatic parasite and other related opportunistic 
parasitic infections (Pozio, 2004).  Further studies 
are required to elucidate the clinical affect of 
this pathogen, particularly among non-receiving 
HAArt patients, the majority of whom are living 
in this region. 
 B. hominis is a cosmopolitan, unicellular, 
polymorphic protozoan parasite. this organism 
is one of the most common intestinal parasites 
found in the large intestine of humans, and the 
fecal-oral route is the mode of transmission.  B. 
hominis has been found in both symptomatic 
and asymptomatic individuals.  this organism 
however remains controversial and is currently 
the subject of extensive debate regarding its role 
as a human pathogen (nigro et al, 2003).  In 
our study, 3 out of 4 positive individuals were 
asymptomatic.  the varying prevalence of B. 
hominis infection from different geographical 
distributions was comparatively high, up to 46% 
(Yakoob et al, 2004a,b).  Further epidemiological 
surveillance in different groups of the population 
is required, therefore, to verify the actual 
prevalence of B. hominis infection in this country. 
the clinical significance of B. hominis has been 
reported worldwide and has certainly gained 
much attention.  In our study, blastocystosis was 
diagnosed in a patient with symptomatic diarrhea. 
the role of this organism as a potential intestinal 
pathogen relating to travelers (Jelinek et al, 
1997); irritable bowel syndrome (IBS) (Ashford 
and Atkinson, 1992; Hussain et al, 1997); 
immunosuppressed patients including cancer, 
hematological malignancy, and HIV/AIDS 
(Devara et al, 1998; tasova et al, 2000; Lebbad 
et al, 2001); hypoalbuminemia and anasarca 
(nassir et al, 2004); and chronic urticaria (Gupta 
and Parsi, 2006) has been consistently reported 
in different settings. In addition, relapse in IBS 
patients was found to be associated with B. 
hominis (Mylonaki et al, 2004).  Supporting 
this clinical aspect, there is a possibility that a 
subgroup of B. hominis could be pathogenic in 
some patients (tungtrongchitr et al, 2004). With 
the advance of molecular studies, we should be 
able to identify this unusual characteristic of B. 
hominis in the near future.  
 Concerning treatment, metronidazole is 
considered a standard drug of choice for treating 
this organism, as was shown in our study. 
nevertheless, previous studies have reported that 
B. hominis cysts were resistant, not only to choline 
(Zaki et al, 1996), but also to metronidazole 
(Zaman and Zaki, 1996; Haresh et al, 1999). 
Interestingly, trimethoprim-sulfamethoxazole 
was found to be highly effective against this 
organism (ok et al, 1999) and in some individuals 
with severe Blastocystis infection (Moghaddam 
et al, 2005).  In addition, B. hominis isolates 
showed greater in vitro susceptibility with 
furazolidone compared with metronidazole and 
complete resistance with ciprofloxacin (Yakoob 
et al, 2004a).  A recent study suggested that 
nitazoxanide could be effective in treating B. 
hominis infection in some patients (rossignol 
et al, 2005).  overall, we recommend further 
study to elucidate the role of B. hominis still; in 
case of the absence of other causes, B. hominis 
should be considered as a pathogen (Carbajal et 
al, 1997).  Also, more clinical drug trial studies, 
including herbal extracts (Sawangjareon and 
Sawangjareon, 2005), are required to verify the 
efficacy of treatments against B. hominis. 
 In this study, only one case was found 
having clinically evidence of filariasis caused 
by Brugia malayi.  Filariasis has been one 
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of the most important parasitic infections in 
Malaysia, where only Wuchereria bancrofti 
and Brugia malayi are reported to cause human 
disease.  Brugian filariasis accounts for about 13 
million cases of the estimated 119 million cases 
worldwide of active infection and chronic disease 
(Jamail et al, 2005).  Almost half of the cases of 
brugian filariasis are confined to Southeast Asia 
countries; while India and China account for the 
other half of the global burden (Michael et al, 
1996). Improvement in diagnostic techniques 
for lymphatic filariasis in this country has been 
remarkably successful and well received. An 
earlier study showed that monoclonal antibodies 
have been used to detect circulating antigens and 
parasite-specific antibodies in filariasis (Abdullah 
et al, 1993).  Subsequently, PCr-ELISA has 
been developed to detect B. malayi infection in 
an area of low endemicity in Malaysia, where 
more infections were detected, and where it 
was more reproducible compared to Southern 
hybridization (rahmah et al, 1998a). Due to 
its high specificity and sensitivity, serological 
detection (IgG4 ELISA) would therefore be 
very useful as a tool in diagnosis if compared 
to thick blood smear examination (rahmah 
et al, 1998b, 2001; Lim et al, 2001).  A further 
study found that this ELISA format would also 
be able to demonstrate the decline in IgG4 titer 
post-treatment (noordin et al, 2003). A rapid 
dipstick test (Brugia rapid) has been used to 
detect specific anti-filarial antibody and has also 
been tested among suspected cases in our study. 
the Brugia rapid is a promising diagnostic tool, 
not only for detecting B. malayi, but also B. timori 
infections; it would be especially useful for the 
brugian filariasis elimination program in terms 
of screening and diagnosis, both in Malaysia and 
related endemic countries worldwide (rahmah 
et al, 2001, 2003a,b; noordin et al, 2003; Supali 
et al, 2004). 
 In conclusion, the diversity of parasitic 
infections is still very much alive in both 
asymptomatic and symptomatic conditions; 
which poses a basic public health problem in this 
tropical rainforest country, Malaysia.  Malaria 
is still the most common parasitic disease; it 
mostly occurs among locals with a history of 
traveling to endemic areas.  toxoplasmosis 
remains one of the most important parasitic 
diseases, and more efforts in terms of diagnosis 
and management are needed to curb the primary 
infection and its consequences of clinical disease. 
Filariasis is generally well controlled in this 
country; however, filariasis control programs 
need to be constantly enforced, particularly in 
certain endemic areas in this region.  Intestinal 
protozoan parasitic infections share their modes of 
transmission and pose a significant public health 
problem.  therefore, more efforts are needed to 
examine the incidence of symptomatic cases, 
particularly emerging parasitic infections like 
cryptosporidiosis or even those with an uncertain 
pathogenic role, such as that of blastocystosis. 
overall, we recommend further studies to be 
carried out as similar epidemiological and clinical 
surveillance to monitor closely the trend of 
parasitic infections periodically.
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